Lenvima

Lenvatinib, the active ingredient in Lenvima, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of certain advanced cancers, including radioactive iodine‑refractory differentiated thyroid cancer, renal cell carcinoma, hepatocellular carcinoma, and endometrial carcinoma, in adult patients.

GNH USA supplies Lenvima as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide. Our distribution network ensures consistent quality and regulatory compliance across regions. We adhere to stringent quality standards and provide reliable logistics support for timely delivery.

Lenvima (lenvatinib) is indicated for several solid tumours that depend on angiogenesis and growth‑factor signalling.

Radioactive iodine‑refractory differentiated thyroid cancer: improves progression‑free survival in adult patients. Renal cell carcinoma: delays disease progression in patients with advanced disease. Hepatocellular carcinoma: extends overall survival in unresectable cases. Endometrial carcinoma: provides clinical benefit in patients with advanced disease.

Common Side Effects: - Fatigue or weakness - Hypertension - Diarrhoea - Nausea or vomiting - Decreased appetite - Hand‑foot skin reaction Serious or Rare Side Effects: - Hepatotoxicity (liver injury) - Cardiac failure or reduced ejection fraction - Severe bleeding or thromboembolic events - Gastrointestinal perforation - Severe hypertension crisis

Patients should be monitored regularly for blood pressure, liver function, and cardiac status during therapy. - Blood pressure monitoring: check at baseline and periodically throughout treatment. - Liver function tests: assess before starting and during therapy. - Cardiac evaluation: perform echocardiogram if risk factors exist. - Pregnancy and lactation: avoid use; discuss contraception with prescriber. - Store at ambient temperature: keep below 25°C in the original container, protect from moisture and light.

Lenvima may interact with several concomitant medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise lenvatinib exposure. - Anticoagulants (e.g., warfarin, direct oral anticoagulants): increase bleeding risk. - High‑dose aspirin or NSAIDs: augment gastrointestinal bleeding. Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may lower drug levels. - Diuretics: can exacerbate hypertension. - Hormonal contraceptives: reduced efficacy may occur; advise alternative methods.